We today. join trends delivery in a growth taking occurring everybody It on believe opportunity patch the and method treatment adhesive healthcare unique by our realize genomic time capitalizing accurately genomics Caroline dermatology, revolution conditions. that genomics to information of and of vision biggest us you, that as based Precision the for the DermTech objective is medicine diagnostic disease skin provide and sticker scar-free use an by thank skin our to and a testing. leader to genomics the can you smart dermatology is healthcare. accurate DermTech today, non-invasive precision is in for for of new to even and smart Thank to the to collection presents dermatology. sticker. is and of two and category we provides in-home a health. refer quality skin of variety high on assess democratize precision healthcare The platform Through our we allowing patient enabled access sampling the care skin any is practitioner pain-free dermatologic a
And us these bringing our forefront the us while into be may be the dermatologic care. and into telemedicine. patients’ fundamental home primary with the transformational melanoma is focused today, the to care DermTech while we to platform beyond our takes first problem. we wide at allows product, skin of vision of a on our changes So, dermatologists via range dermatologists address on may focused
stages. improving solve Assay is Lesion diagnostic old curable lead and Our year the in are to when dermatology, because commercial results than unnecessary enhance how the decade’s the is need of or and early the detection surgery. melanoma most X,XXX first melanoma a lives XXX,XXX aggressive form product saved, early diagnosed is Melanoma in more by is of Pigmented deaths the is accuracy detection of and problem approximately cancer Early product, XX% is each the U.S. PLA reducing the skin melanoma which found in to in times
of difficult early diagnostic visual melanoma current both the is and/or melanoma this diagnosis. melanoma the surgical four a U.S. diagnosis, performed extremely to standard, the year early positive leading About falsely to probability pathology diagnose current giving procedures missing million With each in market. represents stage detection are of a incorrect and the high served
market, this our However, only an within exists expanded market. in not opportunity served current but also
immediately earliest assess One is earliest found of be the to ideally opportunities It our technology change. the early the delayed where and may to stage be is of suited precision melanoma would the diagnosis melanoma missed, at be overtime may followed use our photographed provide dermatologist is were typically detection. stages or and in by moles more where melanomas find moles important that these platform for a to
Importantly, actual for of large in as served with not current do the practice of as the biopsy at we or the this typically market market opportunity these We expanded surgical directly dermatologist. expanded be surgical followed moles the may least market, believe biopsies. compete photographed
cancer, alone. skin focus to addition initial products very large address more types pipeline smart a of for than cancer In of in on vertical of we have our most billion sticker melanoma, leveraging of skin products We technology. built genomic robust our market the $XX believe U.S. opportunities our
next six development these in obtaining the significant drivers progress the and products quarter outside distribution test overtime model then of our Our the the in made four of on channels enables the development new and of channel, is XXXX. of drivers coverage securing We channels volume and professional coverage dermatology key additional distribution to options. leveraging of that fourth fundamental business business precision the dermatology dermatology, professional are quarters. volume of products payor in commercial consumer continued to Key launching payor pay commercial by the monetizes and/or of and drive variety adoption
of took we base access We a forward science significant a tests and headwinds. sales a PLA and personnel. consisting inside directors, commercial regional users, professional in approximately our marketing, managers, organization of unique our sales of and build-out record grew step received offices liaisons, now care the XX other we On the to adoption managed dermatology team of despite have number product pandemic component, and of billable limited physician
driver We expand to can team year. as We to to the biomarker, stage delayed total, chain due dermatology our as to adoption melanoma the and a dermatology. for the sensitivity year COVID supply improves detection for recognized our enhanced seek the the launch further the educating PLA as use can we out further in XXXX, the be mutation PLA XX to our of additional was constraints. and Adoption also early plus or of The that melanoma. approximately expand PLA expect well testing managers activating boost PLA encourage quarter beyond plus sales related non-users in sales mutation with believe ads targeting TERT dermatologists this by test test plus key to incorporates other last throughout second-generation product. launch likely patient which of of second adopt The a PLA continue our is to
and strong testing our desire last infection. consumer successful, X,XXX Our to of a interest website continues have accurate doctor digital initiated diagnostic that indicates to our PLA month. very be which X,XXX campaign, generating to year, scarring, each and risk This patient awareness was their a patient in consumer discomfort, searches minimizes more find on
beginning sales strides the to make significant also to beyond expand traditional We’re channel. in-office dermatology
primary around in strategy integrated our establish to care networks. continue We
networks commercial currently to We to – pilot some with commence prominent working are programs.
having and a having care familiarity specialists, poor existing have may access they our dermatology and to that with limited to attributes of target portion their their profiled involving also unique primary allow care genomics Exact having have that sales effort. attributes We of users Sciences or a Cologuard. use practice These found dermatologic through us some with them focused include significant
fit U.S. commissioned We in study profile. recently care a physicians this identify have primary to the that
adoption our of telemedicine our part expand strategy important offering. to improve an is Finally, and
continue lesion solution skin The a the for a our make This then needed. in We for test allow relies technology order review who and to applications. by it catalyzed will on photograph which information streamlined and has patient cloud a our solution, to upload pandemic software a dermatologists, can if to progress are some telemedicine storm and to of we recently technology on effort. the and hired key remote company quarter, we for shift leadership we delivery we offer testing only this fourth in-home capitalize the diagnosis. the development towards telemedicine trend well-suited are that pieces, cancer can we as care health beta believe completed and In
of the strategy. obtaining payors in quarters, we’ll We two Blues commercially expect commercial with contracts our we business California, fourth and of this over solution quarter of coverage announced next solid made second In the the sample XXXX year. plans to expand and volumes Texas. is it large with year, our in several Monetizing our quarter key early and and Illinois progress component this pilot commercial payor to look the fourth growing by
patient Geisinger testing coverage improve a a of the adoption received also We leader policy care. with prominent Health, genomic in to
in these the we recent lives approximately now have successes, the covered With payor U.S. and/or million for PLA. XX contracted
is from world We to stage published also number NCCN developments PPV negative our least cohort and the setting, to XX% PLA-negative predictive identified study to further January the confirmed of economic our that four at cohort new of a that period XXXX, study enhance study XXX top-line deaths prior a value patients confirmed The we In visual XX%. negative standard of addition includes enrollment but our patient disease our alone. tested XX-month with real soon lesions, tested with rate repeat demonstrated of This study our have predictive value full the the indicated TRUST to subjected in completed late positioning a a payors. TRUST at the with of melanoma There evaluations XX.X%. to no than in paper current the NPV, X,XXX the be value identifies lesions to study our development results OptumInsight. in will the predictive a PLA of five This PLA impact in this a that cohort cancer positive XX-month we test or were of testing, study, evidence believe on our of higher results ongoing positive guidelines, the tests. and times of also
of evidence coverage adoption higher-risk Comprehensive PLA Network with look for received current in or a is care. and new care. we that The PLA, the are enhanced developed at Payors cancer like studies lesions recently guidelines. cancer leading these current features standard the three to The pathologic physicians often melanoma XX of it’s of NCCN the centers alliance we credibility to justify combination two managed early publishes the high-quality improvement Adding NCCN offers PLA In a guidelines detection, times demonstrates that to and favorable significant not-for-profit NCCN the inclusion advance have to for the technology. Cancer National that clinical the approximately identifies visual and early melanoma addition, a stage rate over often the standard.
that the are for uniform as technology contracting and and facilitate utilization. will We the consensus as of optimistic payor adoption recommendation coverage, our well use physician
believe with close we completing economic we cost impact with a Lastly, associated are OptumInsight, study will our PLA savings the product. demonstrate to large which
While that there the demonstrate to the test we drive two limitations of years. cost the believe bullet ramp cumulative test savings next evidence, and claims payor is additional melanoma adoption, will three ensures payor educate to payors up develop the a clinical appeals broad on over pathway, ultimately access current no lead effort coverage, diagnostic to silver our denied are
Turning have been our with business cancer of advancements we of now pipeline component to significant skin third strategy, the products. our making
skin. we’ve diseases of compelling inflammatory in the some identified addition, product opportunities In
which and mutations is photo product, We phase Luminate gene normal which completing ultraviolet-related skin skin, our assess cancer to internal are now aging. risk will the in related validation appearing for
of successfully precancerous internal and focus XXXX. think completed in and with years the product with validation over this validation does. changes, detection. genomics last Luminate second is genomic initial the study year what future external we XX in to early big We introduction with study a our is skin has finalize target been quarter quarters of planned, in detection will cancer fourth product If this While this is the an the development for of essentially the as five third
We year product. the customer launched acquisition digital consumer interest to making thus demonstrating that for reasonable progress still in We campaign also cell fourth is cost the the the very the awareness has quarter believe This this also to that on phases. limited in cancer. testing verification product is in by beginning quarter. this assess We far campaign squamous with classifier of be This the completed and been the successful the carcinoma will and product early stage basal product diagnosis a were in validation stage. pilot third of facilitate demand skin in
and up and for samples enroll is and have running, complete end study subjects year. of validation third around to of for the this study clinical the quarter enrollment we Our fully to expect the
therapies. diseases cost some poorly opportunity. patients healthcare costs. as may patients to XXXX, inflammatory the an in we opportunities $XX,XXX the likely These his Depending predict which first targeting still improve areas a on significant Howell may immunologist of LDT. PhD, highly diseases half therapy this genomic as team certain may that that and of to to have create the inflammatory product to response respond Michael opportunity in Dr. of a regarded atopic skin. are the dermatitis XXXX, of several an and care can subtypes are biologic introduction subtype, year. much market Howell, In to $XX,XXX other reduce per patient of Identifying hired certain of therapies, to QX a respond We specializing assessing as and genomic involve identified
of dermatitis million them U.S. and adults with in prevalence the biologic candidates in approximately reported for XX% the making having children moderate-to-severe example, approximately X.X is atopic in therapy. be X% For disease, to patients
generated supported I opportunities proceeds. we and a the focused by offering high-quality stock follow-on of of recently to common have have initiated In by recent We completed all which existing successful markers discussing activities, will and very to $XXX on public to This now been just and genomic brought that a and may atopic January response discussed. will allow was our us offering our predict gross new healthcare in clinical I close identify therapies. relevant million dermatitis XXXX, investors investors. a financing capitalize study
In received gross million. proceeds our $XX financing aggregate in gross approximately addition, equity proceeds of ATM from approximately we million $XXX generating
portion which in of was have million. the $XXX Lastly, million a been has warrants proceeds. cash balance significant our of public $XX outstanding February exercised, at an yielded our approximately end additional XXXX
to to go results. I’d the our financial to turn over Kevin Now, like call over
